Lineage Cell Therapeutics (LTS:0HNF) Cyclically Adjusted PS Ratio : (As of Jun. 20, 2024)

Lineage Cell Therapeutics Cyclically Adjusted PS Ratio Chart

Lineage Cell Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Cyclically Adjusted PS Ratio		Get a 7-Day Free Trial					28.92	65.71	89.83	34.98	33.06

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cyclically Adjusted PS Ratio	Get a 7-Day Free Trial															43.96	40.19	33.93	33.06	44.43

Competitive Comparison of Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio falls into.

Lineage Cell Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lineage Cell Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Lineage Cell Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Current CPI (Mar. 2024) = 131.7762.

Lineage Cell Therapeutics Quarterly Data

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Lineage Cell Therapeutics  (LTS:0HNF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

Lineage Cell Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics (LTS:0HNF) Business Description